AstraZeneca announces Airsupra (albuterol/budesonide) for adults with asthma is now commercially available in the United States by prescription.
Airsupra received US Food and Drug Administration (FDA) approval in January 2023 for the as-needed treatment or prevention of symptoms of asthma and to help prevent sudden severe breathing problems (asthma attacks) in people aged 18 years and older.
Airsupra contains a short-acting beta2-agonist (SABA) to help relax the smooth muscles of the airways and an inhaled corticosteroid (ICS) to help decrease inflammation in the lungs. Airsupra was approved based on the results from two phase 3 trials, MANDALA and DENALI. In MANDALA, Airsupra was superior to albuterol in reducing the risk of severe asthma exacerbations in patients with moderate to severe asthma. In DENALI, Airsupra had a similar onset of bronchodilation compared to albuterol in patients with mild to moderate asthma.
Read more
